Cellular response to chemoradiotherapy, radiotherapy and chemotherapy in two colorectal cancer cell lines

Radiation Research

Volumn 171, Issue 5, 2009, Pages 562-571

  Adamsen, Birgitte Lid ^a   Kravik, Liza ^a   De Angelis, Paula M ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; H2AFX PROTEIN, HUMAN; HISTONE;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL AGING; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT RESPONSE; APOPTOSIS; CELL CYCLE; CELL STRAIN HCT116; CELL STRAIN HT29; COLORECTAL TUMOR; DRUG EFFECT; METABOLISM; MITOSIS; PATHOLOGY; PHYSIOLOGY; RADIATION EXPOSURE;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; HCT116 CELLS; HISTONES; HT29 CELLS; HUMANS; MITOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67650671926     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1524.1     Document Type: Article

References (39)

1. T. Y. Seiwert, J. K. Salama and E. E. Vokes, The concurrent chemoradiation paradigm - general principles. Nat. Clin. Pract. 4, 86-100 (2007).
2. J. B. Little, H. Nagasawa, P. C. Keng, Y. Yu and C. Y. Li, Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status. J. Biol. Chem. 270, 11033-11036 (1995).
3. - human lymphoblast cell lines. Radiat. Res. 148, 129-134 (1997).
4. R. G. Bristow, Q. Hu, A. Jang, S. Chung, J. Peacock, S. Benchimol and R. Hill, Radioresistant MTp53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation. Oncogene 16, 1789-1802 (1998).
5. H. Huang, C. Y Li and J. B. Little, Abrogation of P53 function by transfection of HPV16 E6 gene does not enhance resistance of human tumour cells to ionizing radiation. Int. J. Radiat. Biol. 70, 151-160 (1996).
6. R. G. Bristow, S. Benchimol and R. P. Hill, The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother. Oncol. 40, 197-223 (1996).
7. P. Fei and W. S. El-Deiry, P53 and radiation responses. Oncogene 22, 5774-5783 (2003).
8. G. D. Wilson, Radiation and the cell cycle, revisited. Cancer Metastasis Rev. 23, 209-225 (2004).
9. R. J. Prestwich, D. Shakespeare and S. Waters, The rationale for and the current role of chemoradiotherapy. J. Radiother. Pract. 6, 11-19 (2007).
10. B. Glimelius, H. Gronberg, J. Jarhult, A. Wallgren and E. Cavallin-Stahl, A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol. 42, 476-492 (2003).
11. B. D. Minsky, A. M. Cohen, N. Kemeny, W. E. Enker, D. P. Kelsen, B. Reichman, L. Saltz, E. R. Sigurdson and J. Frankel, Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J. Clin. Oncol. 10, 79-84 (1992).
12. 1 restriction point into S-phase: implications for fluoropyrimidine radiosensitization. Cancer Res. 60, 92-100 (2000).
13. C. J. McGinn, D. S. Shewach and T. S. Lawrence, Radiosensitizing nucleosides. J. Natl. Cancer Inst. 88, 1193-1203 (1996).
14. J. E. Byfield, 5-Fluorouracil radiation sensitization - a brief review. Invest. New Drugs 7, 111-116 (1989).
15. T. S. Lawrence, J. E. Tepper and A. W Blackstock, Fluoropyrimidine- radiation interactions in cells and tumors. Semin. Radiat. Oncol. 7, 260-266 (1997).
16. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N. Engl. J. Med. 312, 1465-1472 (1985).
17. B. Fisher, N. Wolmark, H. Rockette, C. Redmond, M. Deutsch, D. L. Wickerham, E. R. Fisher, R. Caplan, J. Jones, and Other NSABP Investigators, Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J. Natl. Cancer. Inst. 80, 21-29 (1988).
18. J. E. Krook, C. G. Moertel, L. L. Gunderson, H. S. Wieand, R. T. Collins, R. W. Beart, T. P. Kubista, M. A. Poon, W. C. Meyers and J. A. Mailliard, Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 324, 709-715 (1991).
19. G. D. Wilson, S. M. Bentzen and P. M. Harari, Biologic basis for combining drugs with radiation. Semin. Radiat. Oncol. 16, 2-9 (2006).
20. G. Pizzorno and R. E. Handschumacher, Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. Biochem. Pharmacol. 49, 559-565 (1995).
21. L. L. Vindelov, I. J. Christensen and N. I. Nissen, A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3, 323-327 (1983).
22. B. L. Adamsen, K. L. Kravik, O. P. Clausen and P. M. De Angelis, Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int. J. Oncol. 31, 1491-1500 (2007).
23. G. P. Dimri, X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E. E. Medrano, M. Linskens, I. Rubelj and P. Pereira-Smith, A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92, 9363-9367 (1995).
24. H. Goto, Y. Tomono, K. Ajiro, H. Kosako, M. Fujita, M. Sakurai, K. Okawa, A. Iwamatsu, T. Okigaki and M. Inagaki, Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J. Biol. Chem. 274, 25543-25549 (1999).
25. 2/M checkpoint. EMBO J. 22, 6610-6620 (2003).
26. H. Zhao and H. Piwnica-Worms, ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol. 21, 4129-4139 (2001).
27. M. B. Kastan and D. S. Lim, The many substrates and functions of ATM. Nat. Rev. Mol. Cell. Biol. 1, 179-186 (2000).
28. S. Y. Shieh, M. Ikeda, Y. Taya and C. Prives, DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334 (1997).
29. S. Y. Shieh, Y Taya and C. Prives, DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J. 18, 1815-1823 (1999).
30. J. Bartek and J. Lukas, Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429 (2003).
31. S. Burma, B. P. Chen, M. Murphy, A. Kurimasa and D. J. Chen, ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 276, 42462-42467 (2001).
32. Z. Darzynkiewicz, G. Juan, X. Li, W. Gorczyca, T. Murakami and F. Traganos, Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 27, 1-20 (1997).
33. D. S. Shewach and T. S. Lawrence, Antimetabolite radiosensitizers. J. Clin. Oncol. 25, 4043-4050 (2007).
34. B. Ewald, D. Sampath and W. Plunkett, H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol. Cancer Ther. 6, 1239-1248 (2007).
35. T. T. Paull and M. Gellert, The 3′to 5′exonuclease activity of Mre 11 facilitates repair of DNA double-strand breaks. Mol. Cell 1, 969-979 (1998).
36. E. Rakovitch, W. Mellado, E. J. Hall, T. K. Pandita, S. Sawant and C. R. Geard, Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation. Int. J. Radiat. Oncol. Biol. Phys. 44, 1119-1124 (1999).
37. T. S. Lawrence, R. Burke and M. A. Davis, Lack of effect of TP53 status on fluorodeoxyuridine-mediated radiosensitization. Radiat. Res. 154, 140-144 (2000).
38. J. W. Shay and I. B. Roninson, Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23, 2919-2933 (2004).
39. Z. Han, W. Wei, S. Dunaway, J. W. Darnowski, P. Calabresi, J. Sedivy, E. A. Hendrickson, K. V. Balan, P. Pantazis and J. H. Wyche, Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem. 277, 17154-17160 (2002).